Global consortium formed to combat unproven cell banking services
The International Society for Cell and Gene Therapy has created a group to tackle the rising number of commercial cell bank services that are misleading patients.
List view / Grid view
The International Society for Cell and Gene Therapy has created a group to tackle the rising number of commercial cell bank services that are misleading patients.
This issue includes an investigation into utilising recombinant antibodies for research, a highlight on protein design using computational methods and an examination of the advances in genomic medicine. Also in the issue are articles on next generation sequencing and upstream bioprocessing.
The British Journal of Pharmacology has recommended that all studies it publishes should address sex as an experimental variable.
The ISCT is objecting linking the benefits of cellular immunotherapy with third party offerings of T-cell banking for future therapeutics.
A study has shown that mice and rats become stressed when housed alone, affecting results of pre-clinical trials.
A new report shows that there is still a lack of female representation within the senior roles of the major pharmaceutical companies.
The foundations for protecting human research subjects come from the ethical principles surrounding the Belmont report : Respect for persons, beneficence, and justice.
Unique considerations surrounding the bureaucracy and oversight in the use of human biospecimens in the European Union.
A new report has stated that the majority of medical journals restrict their content for pharmaceutical industry professionals.
The government has issued a letter to the pharmaceutical industry, outlining how to prepare for a no-deal Brexit.
Pharmaceutical company, Sanofi, will eliminate jobs in France and Germany and end new in-house cardiology research programmes.
A study has predicted that the global in vitro toxicology market will rise by 8.2 percent in its forecast period.
13 June 2019 | By Sartorius AG
The new generation of modular premium laboratory balances.
The court held that the defendants adulterated and misbranded a stem cell drug product made from a patient’s adipose tissue.